BioCryst Pharmaceuticals BCRX
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 70th percentile, 5-year average -19.7x
Below its usual level · 36th percentile, 5-year average -7.0x
Near the bottom of its 5-year range · 0th percentile, 5-year average 6.2x
#2576 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -4.93 | – | -6.96 | 36% (cheaper than usual) | – |
| PE | -5.95 | 12.23 | -19.70 | 70% (pricier than usual) | – |
| PS | 2.04 | 2.77 | 6.23 | 0% (cheaper than usual) | #2576 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BCRX.
Sign in to join the discussion.